Myeloma Clinical Trial - Maintenance Therapy Using Lenalidomide in Myeloma

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03832127` - Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients	Phase 1
Completed	`NCT01413178` - A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma	Phase 3
Recruiting	`NCT03641456` - VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma	Phase 2
Completed	`NCT03135925` - Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation	N/A
Terminated	`NCT02907073` - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter	Phase 1/Phase 2
Withdrawn	`NCT02114502` - Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma	Phase 2
Completed	`NCT01700608` - Prospective Observational Study on Plerixafor After Chemotherapy	N/A
Completed	`NCT00794261` - Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma	Phase 2
Completed	`NCT00800839` - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide	Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Recruiting	`NCT05528887` - Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies	Phase 1
Recruiting	`NCT05625971` - Non-invasive MRD Assessment in Multiple Myeloma
Active, not recruiting	`NCT02931942` - Changing Over Time of Ascorbic Acid After Chemotherapy
Active, not recruiting	`NCT05889221` - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma	N/A
Recruiting	`NCT03836690` - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation	Phase 1
Active, not recruiting	`NCT02542657` - Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT01279694` - Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)	Phase 1/Phase 2
Completed	`NCT01191060` - Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years	Phase 3
Terminated	`NCT00983346` - Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients	Phase 2
Completed	`NCT00476294` - Long-Term Follow Up Study for AMD3100 Patients	N/A

NCT number	NCT00430365
Study type	Interventional
Source	University Hospital, Toulouse
Contact
Status	Completed
Phase	Phase 3
Start date	June 2006
Completion date	September 2018

Maintenance Therapy Using Lenalidomide in Myeloma — IFM2005-02

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms